Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
THE SO WHAT
A dermatology-focused biotech heading to public markets to fund eczema and inflammation trials shows that specialized pipelines can still tap equity even in a crowded drug landscape. For healthtech and biotech operators, the bar is clear indications and trial readiness — not platform stories — when you go to raise at scale.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSources: Nuvacore, a six-month-old Sequoia-backed chip startup that's designing a new central processor for data centers, is raising funds at a ~$2.5B valuation
A six-month-old data center CPU startup with no product raising hundreds of millions at a ~$2.5B valuation shows how much capital is hunting for alternatives to incumbent x86 and ARM in AI-era compute. If you’re planning long-lived infra, start tracking these new CPU roadmaps alongside GPUs—lock-in risk is rising on both sides of the socket.
Startups & VentureOxide Computer, which helps companies build their own clouds, raised a $445M Series D led by Eclipse at a $6B valuation, taking its total funding to ~$835M
$445M into Oxide at a $6B valuation is a clear bet that integrated on-prem clouds are a durable alternative to hyperscaler lock-in for AI-era workloads. If you’re planning heavy GPU or data residency spend, you now have to at least model a world where owning the rack — not just renting it — is financially rational.
Startups & VentureThe maker of non-text AI model Jev valued at $7.5B just weeks after launch
A $7.5B valuation on a non-text model weeks after launch says capital is now hunting for modality moats—vision, audio, and other structured data where incumbents are weaker. If your product still treats non-text data as an attachment, assume competitors will move to make it the primary interface.
Startups & VentureRamp Hits $60 Billion Valuation in $1.85 Billion Funding Round
A $60 billion valuation for Ramp says investors still believe in software that wraps finance, data, and AI into a control surface for spend. If you’re selling into CFOs, assume the bar is now integrated workflows and real-time insight—not point tools that sit beside the system of record.